Does RUXOLITINIB Cause Application site exfoliation? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Application site exfoliation have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.0% of all adverse event reports for RUXOLITINIB.
6
Reports of Application site exfoliation with RUXOLITINIB
0.0%
of all RUXOLITINIB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Application site exfoliation From RUXOLITINIB?
Of the 6 reports.
Is Application site exfoliation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Application site exfoliation?
MINOXIDIL (792)
INGENOL MEBUTATE (586)
SUMATRIPTAN (322)
BUPRENORPHINE (143)
DICLOFENAC (109)
PICATO (89)
TRETINOIN (75)
NICOTINE (69)
ESTRADIOL (62)
FENTANYL (59)
Which RUXOLITINIB Alternatives Have Lower Application site exfoliation Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE